Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.

被引：0
|
作者：
Larson, Richard A. [1 ]
Hochhaus, Andreas [2 ]
Saglio, Giuseppe [3 ]
Rosti, Gianantonio [4 ]
Lopez, Jose L. [5 ]
Stenke, Leif [6 ,7 ]
Nakamae, Hirohisa [8 ]
Goldberg, Stuart L. [9 ]
Wang, Ming-Chung [10 ]
Gallagher, Neil J. [11 ]
Hoenekopp, Albert [11 ]
Ortmann, Christine-Elke
Hughes, Timothy P. [12 ]
Kantarjian, Hagop M. [13 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[3] Univ Turin, Div Internal Med & Hematol, Orbassano, Italy
[4] Univ Bologna, Dept Hematol Oncol, Bologna, Italy
[5] Banco Municipal Sangre, Dpt Clin Hematol, Caracas, Venezuela
[6] Karolinska Univ Hosp, Div Hematol, Stockholm, Sweden
[7] Karolinska Inst, Stockholm, Sweden
[8] Osaka City Univ, Grad Sch Med, Osaka 558, Japan
[9] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Leukemia, Hackensack, NJ USA
[10] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med, Kaohsiung, Taiwan
[11] Novartis Pharma AG, Oncol, Basel, Switzerland
[12] Royal Adelaide Hosp, Dept Haematol SA Pathol, Adelaide, SA 5000, Australia
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：944 / 945
页数：2
相关论文
共 50 条
  • [1] The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd.
    Hino, M.
    Matsumura, I.
    Kurokawa, M.
    Amagasaki, T.
    Yanada, M.
    Gallagher, N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year
    Larson, R. A.
    le Coutre, P. D.
    Reiffers, J.
    Hughes, T. P.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N. J.
    Kantarjian, H.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Lobo, Clarisse
    Clark, Richard E.
    Gallagher, Neil J.
    Hoenekopp, Albert
    Haque, Ariful
    Larson, Richard A.
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 94 - 95
  • [4] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    Le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Clark, Richard E.
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd
    Delphine, Rea
    Gautier, Jean-francois
    Breccia, Massimo
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kemp, Charisse
    Gao, Haitao
    Piccolo, Carmen
    Larson, Richard A.
    Hochhaus, Andreas
    BLOOD, 2012, 120 (21)
  • [6] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    Larson, R. A.
    Kim, D.
    Rosti, G.
    Stenke, L.
    Pasquini, R.
    Hoenekopp, A.
    Blakesley, R. E.
    Gallagher, N. J.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR
    Hochhaus, A.
    Lobo, C.
    Pasquini, R.
    Clark, R.
    Kim, D. W.
    Issaragrisil, S.
    le Coutre, P.
    Reiffers, J.
    Kantarjian, H.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N.
    Larson, R.
    Hughes, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 459 - 459
  • [8] DURABLE RESPONSES WITH NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): 18-MONTH RESULTS FROM THE ENESTND STUDY
    Gorospe, Gerry
    Kantarjian, Hagop
    Hochhaus, Andreas
    Larson, Richard
    Saglio, Giuseppe
    Hughes, Timothy
    ONCOLOGY NURSING FORUM, 2011, 38 (02) : E137 - E137
  • [9] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
    Kantarjian, Hagop
    Flinn, Ian W.
    Goldberg, Stuart
    Bunworasate, Udomsak
    Zanichelli, Maria Aparecida
    Nakamae, Hirohisa
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Woodman, Richard Charles
    Blakesley, Rick E.
    Kemp, Charisse N.
    Kalaycio, Matt E.
    Larson, Richard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Nilotinib demonstrates continued superiority vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)-36-months update of the ENESTnd study
    le Coutre, P.
    Gattermann, N.
    Scheid, C.
    Niederwieser, D.
    Ottmann, O. G.
    Duyster, J.
    Blumenstengel, K.
    Bruemendorf, T. H.
    Greil, R.
    Chalandon, Y.
    Valent, P.
    Stegelmann, F.
    Kneba, M.
    Schafhausen, P.
    Saussele, S.
    Frank, O.
    Hughes, T.
    Larson, R. A.
    Saglio, G.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 49 - 49
12345